Trial Profile
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Patients With Influenza at High Risk of Influenza Complications
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Jun 2022
Price :
$35
*
At a glance
- Drugs Baloxavir-marboxil (Primary) ; Oseltamivir
- Indications Influenza virus infections
- Focus Registrational; Therapeutic Use
- Acronyms CAPSTONE-2
- Sponsors Shionogi
- 18 May 2022 Results by deriving data from JapicCTI-153090, NCT02954354; NCT02949011, NCT03959332; KCT0003535, developing pharmacokinetics-time to alleviation of symptoms (PK-TTAS) model to study Baloxavir Marboxil Clinical Efficacy in Different Ethnic Groups with Influenza A or B.published in the Clinical Pharmacology and Therapeutics
- 04 Apr 2022 Results of sub-group analysis assessing efficacy and safety of baloxavir marboxil of in patients with cardiovascular disease, presented at the 71st Annual Scientific Session of the American College of Cardiology.
- 24 Jun 2021 Results of comparative analysis of baloxavir pharmacokinetics and simulated efficacy in chinese individuals and asian patients by using data of baloxavir clinical trials (a Phase I study (NCT03959332), a Phase II study (OwH; T0821), and Phase III studies in OwH (NCT02954354) and high risk (NCT02949011)), presented at the World Microbe Forum 2021